Clinical trial · Observational

Immunophenotyping of Acute b Cell Lymphoblstic Leukemia

Immunophenotyping of Acute b Cell Lymphoblastic Leukemia

NCT04084327CI-TRIAL-00040491unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute iand its correlation with disease outcome

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Acute Leukemia	Acute Leukemia	ONTOLOGY_EXACT	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
stastical analysis	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (3)

measure
overall survival outcome
timeFrame
10 years
description
overall survival outcome
measure
Disease-free survival outcome
timeFrame
10 years
description
Disease-free survival outcome
measure
association of novel CD markers with old markers for assessment of disease outcome
timeFrame
10 years
description
association of novel CD markers with old markers for assessment of disease outcome

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 12 Months
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* New cases admitted to SECI Who didn't receive treatment.Age above 1 years old.

Exclusion Criteria:

* Cases who received treatment Patients below 1 years old.Patients diagnosed as AML or T-ALL

References

Publications (1)

BACKGROUNDKeegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27. PMID 29588374